Senolytic drugs, designed to purge the body of worn-out “senescent” cells, are generating excitement as potential treatments for conditions like type 2 diabetes and Alzheimer’s disease. Yet a new mouse study from U.S. scientists delivers a troubling twist: a popular senolytic combination may inadvertently eat away at the protective myelin sheaths that insulate nerve fibers, producing damage reminiscent of multiple sclerosis – and the effect is stronger in younger brains.
Demylination Spotted in the Brain’s Connector Hub
The team administered a cocktail of dasatinib (a leukemia drug repurposed as a senolytic) and quercetin (a plant flavonoid with antioxidant properties), known as D+Q, to aged 22-month-old C57Bl6/J mice at doses previously shown to extend life. They then focused on the corpus callosum, a thick band of white matter that shuttles information between the brain’s hemispheres. Under transmission electron microscopy, the treated animals displayed significant myelin loss around axons compared with age-matched controls. Results of another experiment surprised the researchers: anterior corpus callosum of young adult mice (3–4 months) showed markedly greater demyelination. Additional staining methods confirmed that D+Q triggered a retreat of myelin mainly in this front section of the structure.
Stressed Cells, Not Dead Cells
Myelin is crafted by oligodendrocytes. Could D+Q simply be killing these cells? Experiments on rat oligodendrocytes exposed to dasatinib, quercetin, or both showed no meaningful rise in cell death; markers like lactate dehydrogenase release and TUNEL staining in aged mouse brains remained flat. Instead, the cocktail stalled the differentiation of oligodendrocyte precursor cells – they failed to fully mature into myelin-producing factories. Even mature oligodendrocytes were affected: they shed their elaborate branching patterns, simplifying into a less complex form that likely loses functional capacity. RNA sequencing revealed a distinct stress signature. The combination activated endoplasmic reticulum stress and unfolded protein response pathways, while simultaneously suppressing myelin-promoting genes such as Fyn and Myrf. The transcriptome did not, however, indicate a clean reset to an embryonic state, suggesting the cells are stuck in a stressed, partially dedifferentiated limbo.
A Window into Multiple Sclerosis Repair?
The sight of oligodendrocytes backsliding intrigued the researchers because analogous cell populations have been found in the brains of people with multiple sclerosis. The authors hypothesize that in MS, myelin-generating cells may undergo similar stresses and slip back to a more juvenile stage, yet retain the potential to be nudged forward again. If true, such cells could represent a latent reservoir for repair therapy. The study thus delivers a dual message: D+Q’s demyelinating side effect is a red flag for senolytic trials, particularly in young or vulnerable individuals, but the mechanism behind it might also illuminate a path to remyelination in chronic demyelinating diseases. For now, the findings underscore just how finely balanced the brain’s cellular maintenance machinery is – and why promising anti-aging strategies need thorough neurological assessment.
Publication date: 2026.03.27
Source: Lombardo E.R. et al Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum. Proc Natl Acad Sci U S A. 2026 Mar 24;123(12):e2524897123. doi: 10.1073/pnas.2524897123. Epub 2026 Mar 17. PMID: 41843680; PMCID: PMC13012039. https://www.pnas.org/doi/10.1073/pnas.2524897123